510(k) device
Aim-V (R) Medium, Model 087-0112
Invitrogen Corporation · Media, Culture, Ex Vivo, Tissue And Cell (NDS, Class II) · First FDA decision Dec 23, 2002, newest Dec 23, 2002Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Aim-V Medium"
MAUDE reports
0
Brand "Aim-V Medium", since 2015
PubMed studies
39
Mentioning "Aim-V Medium"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Aim-V (R) Medium, Model 087-0112
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K022086 · Decided Dec 23, 2002 · 179 days after receipt
Device type: Media, Culture, Ex Vivo, Tissue And Cell (NDS) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Aim-V Medium", any status and sponsor, newest update first.
- To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor SurgeryRecruiting
Chang Gung Memorial HospitalAcademic, hospital or other
NCT06221020 · 70 participants (planned) · Start Dec 12, 2023 · Primary completion Nov 30, 2026
Device: TIB Olfactory Test Device · For: Enhanced Recovery After Surgery; Pituitary Tumor; Postoperative Complications
Sites: Kaohsiung City, Taiwan
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Aim-V Medium", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NDS
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- GIBCO CTS AIM V Serum-Free Media (SFM), Model Number 0870112BK. Tissue and cell culture medium.Terminated
Z-2543-2018 · Started May 10, 2018 · Posted by FDA Jul 25, 2018
Reason given: It has been determined that the fill port tube seal integrity was compromised during the manufacture of the product lot. This may cause media to leak out of the primary sterile packaging into outer non-sterile dust cover packaging, and subsequently mold may grow in the pooled, leaked media.
Cause as FDA categorized it: Unknown/Undetermined by firm · Device type: Media, Culture, Ex Vivo, Tissue And Cell (NDS)
Published research
The most relevant PubMed records for "Aim-V Medium"[tiab]. The summary above synthesizes these.
- Influence of various medium environment to in vitro human T cell culture.
Xu H, Wang N, Cao W, et al. · In Vitro Cell Dev Biol Anim · 2018
- Tumor-infiltrating lymphocytes from nonrenal urological malignancies.
Haas GP, Solomon D, Rosenberg SA · Cancer Immunol Immunother · 1990
- Cultivation and characterization of canine skin-derived mast cells.
Kawarai S, Masuda K, Ohmori K, et al. · J Vet Med Sci · 2010Research Support, Non-U.S. Gov't
- Optimization of culture conditions for HBV-specific T cell expansion in vitro from chronically infected patients.
Wang L, Chen H, Yang Y, et al. · BMC Biotechnol · 2024
- Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.
Harada Y, Imataki O, Heike Y, et al. · J Immunother · 2005Research Support, Non-U.S. Gov't
- Long-term cultivation of functional human macrophages in Teflon dishes with serum-free media.
Helinski EH, Bielat KL, Ovak GM, et al. · J Leukoc Biol · 1988Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells.
Imataki O, Heike Y, Ishida T, et al. · J Immunother · 2006Research Support, Non-U.S. Gov't
- Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
Lamers CH, van de Griend RJ, Braakman E, et al. · Int J Cancer · 1992Research Support, Non-U.S. Gov't
- Banking of human ovarian tissue potentially contaminated by cancer cells: experimental model for study of cryo-stability of these cells.
Isachenko V, Du X, Isachenko E, et al. · Cell Tissue Bank · 2020
- A dual neutrophil-T cell purification procedure and methodological considerations in studying the effects of estrogen on human Th17 cell differentiation.
Xiu F, Sabz Ali Z, Palaniyar N, et al. · J Immunol Methods · 2019Research Support, Non-U.S. Gov't
- Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors.
Knazek RA, Wu YW, Aebersold PM, et al. · J Immunol Methods · 1990
- Comparison of the Effect of Different Conditioning Media on the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes: Towards Engineering Next-Generation Autologous Growth Factor Cocktails.
Moog P, Hughes J, Jiang J, et al. · Int J Mol Sci · 2023
Other devices of this type
Also filed under product code NDS.
- Msc SfmYocon Biology Technology Company · 510(k) 2024
- MoFi Cell Culture Basal MediumDuogenic Stemcells Corporation · 510(k) 2024
- PRIME-XV FreezIS DMSO-Free MDFujifilm Irvine Scientific · 510(k) 2023
- Ct-StorEnergy Delivery Solutions · 510(k) 2021
- Optmizer Cts T-Cell Expansion Serum Free MediumLife Technologies, Inc. · 510(k) 2012
- Stempro Msc SfmLife Technologies Corporation · 510(k) 2011
- Knockout Sr Medium, Knockout Sr Xenofree Medium Model 10828, 12618Life Technologies Corporation · 510(k) 2010
- Dulbecco's Modified Eagle Medium (Dmem)Life Technologies, Inc. · De Novo 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.